Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 5, 2009, Pages 575-577

  Misu, T ^a   Takano, R ^a   Fujihara, K ^a   Takahashi, T ^b   Sato, S ^c   Itoyama, Y ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yonezawa National Hospital   (Japan)

^c KOHNAN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; CORTICOSTEROID; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN S100B; BIOLOGICAL MARKER; PROTEIN S 100;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISABILITY; DISEASE MARKER; ENCEPHALOMYELITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; SPINAL CORD VASCULAR DISEASE; ASTROCYTE; CEREBROSPINAL FLUID; GENETICS; MIDDLE AGED; PATHOLOGY; POSTVACCINAL ENCEPHALITIS; SPINAL CORD;

ADULT; AGED; AQUAPORIN 4; ASTROCYTES; BIOLOGICAL MARKERS; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; S100 PROTEINS; SPINAL CORD;

EID: 65449122027     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.150698     Document Type: Article

References (25)

1. Devic E. Myélite subaiguë compliquée de néurite optique. Bull Med 1894;8:1033-4.
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14. (Pubitemid 29442132)
3. Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002;125:2460-8. (Pubitemid 35303505)
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12. (Pubitemid 39626806)
5. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-7. (Pubitemid 41186945)
6. Misu T, Fujihara K, Nakamura M, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 2006;209:269-75. (Pubitemid 43905560)
7. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224-34. (Pubitemid 47355951)
8. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194-205. (Pubitemid 47355941)
9. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9. (Pubitemid 43958540)
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
11. Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5771-92. (Pubitemid 47049772)
12. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-43. (Pubitemid 47355956)
13. Itoyama Y, Ohnishi A, Tateishi J, et al. Spinal cord multiple sclerosis lesions in Japanese patients: Schwann cell remyelination occurs in areas that lack glial fibrillary acidic protein (GFAP). Acta Neuropathol (Berl) 1985;65:217-23. (Pubitemid 15173183)
14. Miyazawa I, Nakashima I, Petzold A, et al. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 2007;68:865-7. (Pubitemid 46568541)
15. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years. Neurochem Res 2000;25:1439-51.
16. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995;133:61-5.
17. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462-73. (Pubitemid 34755162)
18. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Meth 1994;51:197-204. (Pubitemid 24110093)
19. Petzold A, Keir G, Green AJE, et al. An ELISA for glial fibrillary acidic protein. J Immunol Meth 2004;287:169-77. (Pubitemid 38510218)
20. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-31. (Pubitemid 350294677)
21. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl 2006:373-81. (Pubitemid 44622226)
22. Katsarou Z, Bostantjopoulou S, Hatzizisi O, et al. Immune factors or depression? Fatigue correlates in Parkinson's disease. Rev Neurol 2007;45:725-8.
23. Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005;64:1267-9. (Pubitemid 40490533)
24. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-4. (Pubitemid 43989814)
25. Maes M, Mihaylova I, Kubera M, et al. Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett 2007;28:463-9. (Pubitemid 47577726)